Sensus Healthcare Inc (NASDAQ:SRTS) to Post Q3 2018 Earnings of ($0.12) Per Share, B. Riley Forecasts

Sensus Healthcare Inc (NASDAQ:SRTS) – Equities researchers at B. Riley issued their Q3 2018 earnings estimates for shares of Sensus Healthcare in a research note issued to investors on Tuesday, September 25th, according to Zacks Investment Research. B. Riley analyst A. D’silva anticipates that the company will post earnings per share of ($0.12) for the quarter. B. Riley currently has a “Buy” rating and a $12.50 target price on the stock. B. Riley also issued estimates for Sensus Healthcare’s Q4 2018 earnings at ($0.02) EPS, FY2018 earnings at ($0.25) EPS, Q1 2019 earnings at ($0.06) EPS, Q2 2019 earnings at $0.04 EPS, Q3 2019 earnings at ($0.04) EPS, Q4 2019 earnings at $0.07 EPS, FY2019 earnings at $0.02 EPS and FY2020 earnings at $0.24 EPS.

Several other equities analysts have also recently commented on the company. HC Wainwright initiated coverage on Sensus Healthcare in a report on Monday, August 27th. They issued a “buy” rating and a $14.00 price target for the company. initiated coverage on Sensus Healthcare in a report on Friday, July 6th. They issued a “buy” rating and a $12.25 price target for the company. Roth Capital initiated coverage on Sensus Healthcare in a report on Wednesday, August 1st. They issued a “buy” rating and a $12.50 price target for the company. Finally, Maxim Group upped their price target on Sensus Healthcare from $9.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, September 19th. Six investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $12.25.

Sensus Healthcare stock traded up $0.10 during trading hours on Friday, hitting $7.16. The stock had a trading volume of 43,753 shares, compared to its average volume of 30,207. The company has a quick ratio of 3.49, a current ratio of 3.80 and a debt-to-equity ratio of 0.39. The stock has a market cap of $134.80 million, a price-to-earnings ratio of -25.57 and a beta of -1.29. Sensus Healthcare has a fifty-two week low of $4.91 and a fifty-two week high of $8.88.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, August 2nd. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The business had revenue of $6.06 million for the quarter, compared to the consensus estimate of $6.36 million. Sensus Healthcare had a negative net margin of 13.07% and a negative return on equity of 26.74%.

Several institutional investors and hedge funds have recently modified their holdings of SRTS. Commonwealth Equity Services LLC acquired a new position in shares of Sensus Healthcare in the 1st quarter worth approximately $140,000. Paradigm Capital Management Inc. NY acquired a new position in shares of Sensus Healthcare in the 2nd quarter worth approximately $152,000. BlackRock Inc. acquired a new position in shares of Sensus Healthcare in the 2nd quarter worth approximately $164,000. Renaissance Technologies LLC raised its holdings in shares of Sensus Healthcare by 141.1% in the 2nd quarter. Renaissance Technologies LLC now owns 27,488 shares of the company’s stock worth $200,000 after buying an additional 16,088 shares in the last quarter. Finally, Perkins Capital Management Inc. acquired a new position in shares of Sensus Healthcare in the 2nd quarter worth approximately $1,792,000. 7.25% of the stock is owned by institutional investors and hedge funds.

In other news, insider Joseph C. Sardano sold 6,170 shares of the stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $7.50, for a total value of $46,275.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 12,854 shares of company stock valued at $96,567. 41.10% of the stock is currently owned by insiders.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Further Reading: What is the balance sheet?

Get a free copy of the Zacks research report on Sensus Healthcare (SRTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply